Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CEO: With NDA under review, solid bank account, Yaupon's a catch

This article was originally published in Scrip

Executive Summary

With $14.4 million in new funding added to its coffers and a new drug application (NDA) under review at the US FDA for a patent-protected medicine that stands to be the first-of-its-kind on the US market for a rare disease – which could mean an additional seven years of data exclusivity protection – specialty pharma Yaupon Therapeutics has become an attractive potential partner or acquisition target for any drug maker to consider, said Chairman and CEO Steve Tullman.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC014046

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel